Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
Marco Valgimigli(University of Bern), Giovanni Pedrazzini(Università della Svizzera italiana), Farzin Beygui(Normandie Université), Adel Aminian(Grand Charleroi Hospital), Willem Theodoor Ruifrok(Treant Zorggroep), Dario Bongiovanni(Augsburg University), Dik Heg, Pascal Vranckx(Jessa Hospital), Kenji Andò(Kokura Memorial Hospital), Al Mafragi, Atul Abhyankar(Shree O.H. Nazar Ayurved College Shree Swami Atmanand Saraswati Ayurved Hospital), Dimitar Karageorgiev, Stefano Garducci(Azienda Ospedaliera di Desio e Vimercate), José Francisco Díaz Fernández(Hospital Juan Ramón Jiménez), Krzysztof Reczuch(Wroclaw Medical University), Thomas Hovasse(Hôpital Privé Jacques Cartier), Majdi Halabi, Béla Merkely(Semmelweis University), Helen Routledge(Worcestershire Royal Hospital), Jehangir Din(Royal Bournemouth Hospital), Pieter C. Smits(Maasstad Ziekenhuis), Thomas Cuisset(Assistance Publique Hôpitaux de Marseille), Jan G.P. Tijssen(Amsterdam UMC Location University of Amsterdam), Enrico Frigoli(University of Bern), Fazila‐Tun‐Nesa Malik(National Heart Foundation Hospital & Research Institute), Loïc Belle(Centre Hospitalier Annecy Genevois)
Cited by 78
Related Papers
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus
|New England Journal of Medicine|2002|1.6k